VLDLR and metabolic syndrome: Dyslipidemia emerges early in CKD, distinguished from the MAFLD pattern by reduced activity of LPL and hepatic lipase, down-regulation of VLDL receptors (VLDLR) in muscle and adipose tissue, and diminished hepatic LDL-receptor-related protein 1 (LRP-1) [45,46].